670 related articles for article (PubMed ID: 15929121)
21. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases.
Vescovi P; Merigo E; Manfredi M; Meleti M; Fornaini C; Bonanini M; Rocca JP; Nammour S
Photomed Laser Surg; 2008 Feb; 26(1):37-46. PubMed ID: 18248160
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonate-associated osteonecrosis. A clinician's reference to patient management.
Grewal VS; Fayans EP
N Y State Dent J; 2008 Jan; 74(1):38-44. PubMed ID: 18402375
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients.
Thumbigere-Math V; Sabino MC; Gopalakrishnan R; Huckabay S; Dudek AZ; Basu S; Hughes PJ; Michalowicz BS; Leach JW; Swenson KK; Swift JQ; Adkinson C; Basi DL
J Oral Maxillofac Surg; 2009 Sep; 67(9):1904-13. PubMed ID: 19686928
[TBL] [Abstract][Full Text] [Related]
24. Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?
Mawardi H; Treister N; Richardson P; Anderson K; Munshi N; Faiella RA; Woo SB
J Oral Maxillofac Surg; 2009 Mar; 67(3):593-601. PubMed ID: 19231786
[TBL] [Abstract][Full Text] [Related]
25. Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: a case report and literature review.
Bedogni A; Bettini G; Totola A; Saia G; Nocini PF
J Oral Maxillofac Surg; 2010 Jul; 68(7):1662-6. PubMed ID: 20561470
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases.
Salesi N; Pistilli R; Marcelli V; Govoni FA; Bozza F; Bossone G; Venturelli V; Di Cocco B; Pacetti U; Ciorra A; Di Fonso C; Cortesi E; Veltri E; Vecchione A
Anticancer Res; 2006; 26(4B):3111-5. PubMed ID: 16886642
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.
Infante Cossío P; Cabezas Macián A; Pérez Ceballos JL; Palomino Nicas J; Gutiérrez Pérez JL
Med Oral Patol Oral Cir Bucal; 2008 Jan; 13(1):E52-7. PubMed ID: 18167482
[TBL] [Abstract][Full Text] [Related]
28. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
[TBL] [Abstract][Full Text] [Related]
29. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
[TBL] [Abstract][Full Text] [Related]
30. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
Carlson ER; Basile JD
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
[TBL] [Abstract][Full Text] [Related]
31. The use of bisphosphonates in cancer patients.
Wu S; Dahut WL; Gulley JL
Acta Oncol; 2007; 46(5):581-91. PubMed ID: 17562434
[TBL] [Abstract][Full Text] [Related]
32. [Osteonecrosis of the mandible induced by intravenous bisphosphonates in oncological patients].
Carvalho A; Amaral Mendes R; Carvalho D; Carvalho JF
Acta Med Port; 2008; 21(5):505-10. PubMed ID: 19187694
[TBL] [Abstract][Full Text] [Related]
33. Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw--a serial case analysis.
Chiu CT; Chiang WF; Chuang CY; Chang SW
J Oral Maxillofac Surg; 2010 May; 68(5):1055-63. PubMed ID: 20403529
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
35. [Surgical treatment of maxillary osteonecrosis due to bisphosphonates using an Er:YAG (2940 nm) laser. Discussion of 17 clinical cases].
Vescovi P; Merigo E; Manfredi M; Meleti M; Fornaini C; Bonanini M; Rocca EP; De Moor RJ; Nammour S
Rev Belge Med Dent (1984); 2009; 64(2):87-95. PubMed ID: 19681350
[TBL] [Abstract][Full Text] [Related]
36. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
Assael LA
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813
[TBL] [Abstract][Full Text] [Related]
37. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
38. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy.
Melo MD; Obeid G
J Can Dent Assoc; 2005 Feb; 71(2):111-3. PubMed ID: 15691429
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonate-related osteonecrosis of the jaws.
Yeo AC; Lye KW; Poon CY
Singapore Dent J; 2005 Dec; 27(1):36-40. PubMed ID: 16438267
[TBL] [Abstract][Full Text] [Related]
40. Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.
Gallego L; Junquera L
Br J Oral Maxillofac Surg; 2009 Jan; 47(1):67-8. PubMed ID: 18639371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
